Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $9.2252W HIGH $22.02
Volume
2.88 M
Value Traded
25.22 M
Short % Float
16.39%
+1.68%Week
+1.12%1 Month
+41.88%3 Month
+33.52%6 Month
-75.23%5 Year
-51.22%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
2.01 B
EPS (TTM)
-12.50
P/E Ratio
-
Ent. Value
4.91 B
Total Shares
138.77 M
Float Shares
138.16 M
Insiders
0.44%
Institutions
111.28%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
PRGO Catalyst Timeline
Dated clinical, regulatory and corporate events for Perrigo Company plc
Catalyst Timeline
Dated clinical, regulatory & corporate events for Perrigo Company plc
555Total events
1Upcoming
133Tier-1 (high impact)
2014 to 2028Coverage
Event history 50
◆Pipeline PrioritizationCorporate
Strategic reviews of Infant Formula and Oral Care businesses ongoing
◆Oral PresentationPresentation
Perrigo to present at Oppenheimer 26th Annual Consumer Growth & E-Commerce Conference
◆Management ChangeCorporate
Patrick Lockwood-Taylor resigns as President and CEO and Board member
◆Oral PresentationPresentation
Perrigo to present at UBS Global Consumer and Retail Conference
▲Restructuring LayoffsCorporate
Launching new operational enhancement program with $80-100M annualized savings
◆AcquisitionCorporate
Sale of Dermacosmetics business on track to close in Q1 2026
Dermacosmeticssource ↗
▼Restructuring LayoffsCorporate
Potential additional goodwill impairment up to $350M in Q1 2026
◆Program DiscontinuationCorporate
Initiates strategic review of Infant Formula business
Infant Formulasource ↗
◆R&D DayPresentation
Perrigo to attend Barclays Global Consumer Staples Conference for one-on-one investor meetings
◆Oral PresentationPresentation
Perrigo to present at Canaccord Genuity 45th Annual Growth Conference
▲Partnership / LicenseCorporate
Perrigo signs agreement to sell Dermacosmetics business to KKR for up to $327M
◆AcquisitionCorporate
Perrigo signs agreement to sell Dermacosmetics business to KKR for up to €327 million
◆Management ChangeCorporate
Matt Winterman appointed EVP Product Supply, Operations Strategy & Transformation Officer
◆Oral PresentationPresentation
Perrigo to present at Oppenheimer 25th Annual Consumer Growth & E-Commerce Conference
◆Oral PresentationPresentation
Presentation at UBS 2025 Global Consumer and Retail Conference
▲Product LaunchOpillApprovedPost-Market
WNBA on Campus presented by Opill at University of South Carolina
contraceptionsource ↗
▲Product LaunchOpillApprovedPost-Market
Opill launches multi-state college tour and expands WNBA partnership
contraceptionsource ↗
▲Partnership / LicenseOpillApprovedCorporate
Opill continues multiyear partnership with WNBA and BWHI
contraceptionsource ↗
Past FDA Catalysts and PDUFA Decisions
How PRGO actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2023-07-13 | Opill (norgestrel) | PDUFA Date Approved | PDUFA |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
C46 / 100
Pipeline Score
$957M
Pipeline Value
$17.6B
Commercial Value
Undervalued
Valuation Signal
2
Drugs Scored
1.6x
rNPV / MCap
Top 26%
Small Cap(rank 172 of 658)
Percentile Rank
Perrigo Company plc carries a moderate pipeline score (46/100), with $1.5B risk-adjusted pipeline value, led by 2% urea/20% glycerol in Dermatitis, Atopic (Phase 2), across $86B in total addressable markets.
Commercial products (revenue basis: trailing 4 quarters of total revenue (10-K and 10-Q), to Jun 2026) Revenue $4.1B x 4.2 = $17.6B
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2% urea/20% glycerol Small moleculeCompletedNCT03901144 | Dermatitis, Atopic | Phase 2 | COMPLETED | 50 | Dec 10, 2019 |
Clinical Trial Results
Readouts, endpoints and source filings for every PRGO program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Parker Geoffrey M.Director | Option | 1,263 34,480 held | $13.66 | 09/11/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in PRGO
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| INTEGRAL HEALTH ASSET MANAGEMENT, LLC | 2.2 % (46.7 %) | 11.41 M | 320.00 K | 75.2% ( 137.35 K) |
PRGO Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2027-05-21 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How PRGO ranks across every disease it competes in
Competitive Position is a premium feature
See how PRGO ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialPRGO News
PRGOPerrigo to Attend the Barclays Global Consumer Conference
Perrigo Company plc announced that Interim President and CEO Albert Manzone and CFO Eduardo Bezerra will participate in investor meetings at the Barclays Global Consumer Conference on September 10, 2026. This event underscores Perrigo's commitment to engaging with investors and promoting its self-care products. The company has a long history in the health and wellness sector.
Read more →PRGO▲ +23.1%on this news
Perrigo Reports Second Quarter 2026 Financial Results From Continuing Operations
Perrigo Company plc reported its second quarter 2026 financial results, showing a decline in Core net sales by 3.1% year-over-year, attributed to ongoing category softness and macroeconomic challenges. However, the company achieved market share growth and completed the divestiture of its Dermacosmetics business. Perrigo reaffirmed its full-year outlook, anticipating stronger performance in the second half of 2026.
Read more →PRGOPerrigo Announces Quarterly Dividend
Perrigo Company plc has announced a quarterly dividend of $0.29 per share, payable on September 15, 2026. This decision reflects the company's strong financial position and commitment to returning value to shareholders. The dividend is part of Perrigo's ongoing strategy to support its consumer self-care product offerings.
Read more →PRGOPerrigo to Present at the Canaccord 46th Annual Growth Conference
Perrigo Company plc announced that its Interim President and CEO, Albert Manzone, along with CFO Eduardo Bezerra, will present at the Canaccord 46th Annual Growth Conference on August 12th. The webcast will be available on Perrigo's investor relations website. The company emphasizes its commitment to providing high-quality self-care solutions.
Read more →PRGOPerrigo to Release Second Quarter 2026 Financial Results on August 5, 2026
Perrigo Company plc has announced that it will release its second quarter 2026 financial results on August 5, 2026. The release will be followed by a conference call hosted by Interim President and CEO Albert Manzone and CFO Eduardo Bezerra. The call will be accessible via webcast and phone, with a replay available for a week after the event.
Read more →PRGOPerrigo Announces Appointment of Two New Independent Directors to Board
Perrigo Company plc has appointed Salman Amin and Omer Gajial as independent directors, effective June 30, 2026. Both directors bring extensive experience in consumer products and retail, which is expected to support Perrigo's strategic priorities. The appointments are seen as a positive step towards enhancing the company's operational excellence and growth.
Read more →PRGO▲ +7.2%on this news
Perrigo Announces Leadership Transition Albert A. Manzone Appointed Interim President and CEO
Perrigo Company plc has appointed Albert A. Manzone as Interim President and Chief Executive Officer following the resignation of Patrick Lockwood-Taylor due to personal conduct issues. The Board has initiated a search for a permanent successor while expressing confidence in Manzone's leadership capabilities, given his extensive experience and familiarity with the company. Despite the leadership change, Perrigo has reaffirmed its financial outlook for 2026 and aims to maintain its strategic direction during this transition.
Read more →PRGO▲ +7.2%on this news
Perrigo Announces Leadership Transition
Perrigo Company plc has appointed Albert A. Manzone as Interim President and CEO following the resignation of Patrick Lockwood-Taylor due to personal conduct issues. The Board is conducting a search for a permanent successor. Manzone aims to maintain continuity and support the leadership team while reaffirming the company's financial outlook for 2026.
Read more →PRGOPerrigo to Present at the Oppenheimer 26th Annual Consumer Growth & E-Commerce Conference
Perrigo Company plc announced that President and CEO Patrick Lockwood-Taylor and CFO Eduardo Bezerra will present at the Oppenheimer 26th Annual Consumer Growth & E-Commerce Conference on June 9th. The presentation will be accessible via webcast on Perrigo's website. The company is recognized for its extensive experience in consumer health products.
Read more →PRGO▲ +5.3%on this news
Perrigo Reports First Quarter 2026 Financial Results From Continuing Operations
Perrigo Company plc reported its first quarter 2026 financial results, showing a commitment to transforming its business despite a challenging environment. The company is focused on a category-led operating model and has reaffirmed its full-year guidance, supported by growth in specific segments like Women's Health. However, net sales have declined significantly, and operating income in the Self Care segment has decreased sharply.
Read more →PRGOPerrigo Completes Divestiture of Dermacosmetics Business Perrigo Company plc (NYSE: PRGO) ( Perrigo or the Company ), a leading global provider of consumer health products, today announced that it has...
Perrigo Company plc has completed the divestiture of its branded Dermacosmetics business to Karo Healthcare for up to €332.6 million, which includes €305.6 million in upfront cash. This move is part of Perrigo's Three-S strategy aimed at stabilizing, streamlining, and strengthening the company. The proceeds from this transaction are intended primarily for debt reduction, thereby improving financial flexibility. The Dermacosmetics business had generated approximately €120 million in net sales in 2025, representing about 5% of Perrigo's adjusted operating income.
Read more →PRGOPerrigo to Release First Quarter 2026 Financial Results on May 6, 2026
Perrigo Company plc has announced that it will release its first quarter 2026 financial results on May 6, 2026. The company will host a conference call at 8:30 A.M. (EST) to discuss these results, which will be accessible via webcast or phone. A replay of the call will be available for a week following the event.
Read more →PRGOPERRIGO COMPANY PLC RECONCILIATION OF NON-GAAP MEASURES SELECT CONSOLIDATED INFORMATION QUARTERS AND CALENDAR YEAR TO DATE 2025 (in millions) (unaudited) Three Months Ended Twelve Months Ended Consolidated Continuing Ope
Perrigo Company PLC provided detailed information regarding its consolidated financials and non-GAAP measures for the fiscal year and quarters ended in 2025. The report indicated strong sales in the Self Care segment, totaling $2,533.5 million for the year, while total adjusted operating income reached $682.6 million. However, the company also reported a substantial goodwill impairment charge of $1.3 billion in the fourth quarter and a significant operating loss of $1,287.2 million for the same period, highlighting financial challenges in specific areas of its operations.
Read more →PRGOPerrigo to Present at the UBS Global Consumer and Retail Conference
Perrigo Company plc announced that its President and CEO, Patrick Lockwood-Taylor, will present at the UBS Global Consumer and Retail Conference on March 11th. The presentation will be accessible via a webcast on the company's investor relations website. Perrigo is recognized for its extensive experience in consumer health solutions, particularly in the OTC market.
Read more →PRGOPerrigo Reports Fourth Quarter and Fiscal Year 2025 Financial Results From Continuing Operations
Perrigo Company plc reported its financial results for the fourth quarter and fiscal year 2025, highlighting a decline in net sales and a significant goodwill impairment charge. Despite these challenges, the company gained market share in store brands and launched an operational enhancement program aimed at generating substantial cost savings. Looking ahead, Perrigo has outlined its fiscal year 2026 outlook, which reflects ongoing market pressures but also opportunities for growth.
Read more →PRGOPerrigo Announces Quarterly Dividend Perrigo Company plc (NYSE: PRGO), a leading global provider of consumer products, today announced that its Board of Directors has approved a...
Perrigo Company plc announced the approval of a quarterly dividend of $0.29 per share, which translates to an annualized rate of $1.16. This dividend is set to be paid on March 24, 2026, to shareholders who are on record by March 2, 2026. The company emphasizes its role as a leading provider of consumer health solutions, leveraging its business model to support brand investments while providing accessible OTC self-care products.
Read more →PRGOPerrigo to Release Fourth Quarter and Fiscal Year 2025 Financial Results on February 26, 2026
Perrigo Company plc announced it will release its fourth quarter and fiscal year 2025 financial results on February 26, 2026. The company will host a conference call at 8:30 A.M. (EST) to discuss these results, which will be accessible via webcast and phone. A replay of the call will be available shortly after the event.
Read more →PRGOPerrigo to Attend Morgan Stanley Global Consumer & Retail Conference
Perrigo Company plc announced its participation in the Morgan Stanley Global Consumer & Retail Conference, scheduled for December 2, 2025. President and CEO Patrick Lockwood-Taylor, along with CFO Eduardo Bezerra, will engage in one-on-one investor meetings. This event underscores Perrigo's commitment to investor relations and its position in the consumer health market.
Read more →About Perrigo Company plc
HeadquartersTHE SHARP BUILDING, DUBLIN 2, L2, D02 TY74
BIOPHARMAWATCH ELITE PLUS
Trade the next PRGO catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime